Response Genetics, Inc. To Release Fourth Quarter And Full-Year 2010 Financial Results And Operational Update On March 29, 2011
Response Genetics, Inc. (Nasdaq:RGDX),a company focused on the
development and commercialization of molecular diagnostic tests for
cancer, will announce its fourth quarter and full-year 2010 financial
results and an...
Response Genetics, Inc. (Nasdaq:RGDX),a company focused on the development and commercialization of molecular diagnostic tests for cancer, will announce its fourth quarter and full-year 2010 financial results and an operational update in a press release to be issued before the market opens on Tuesday, March 29, 2011. About Response Genetics, Inc. Response Genetics Inc. (“RGI”) is focused on the development and sale of molecular diagnostic tests for cancer. RGI’s technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin-embedded specimens. In addition to diagnostic testing services, the Company generates revenue from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. RGI was founded in 1999 and its principal headquarters are located in Los Angeles, California. For more information, please visit www.responsegenetics.com. Forward-Looking Statement NoticeExcept for the historical information contained herein, this press release and the statements of representatives of RGI related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions, such as the ability of the Company to announce its financial statements for the fourth quarter of 2010 and full-year 2010 financial results, the ability of the Company to provide an operational update, the ability of the Company to continue to collect revenues on sales of its ResponseDX tests, and other statements identified by words such as “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans” or similar expressions.These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.